The biosimilar's safety and immunogenicity profiles were found to be comparable to those of the reference product in the ...

This organization has no public members. You must be a member to see who’s a part of this organization.

Unveiling oncology and non-oncology drug approvals and withdrawals of USFDA and EMA,” published in the January 2025 issue of ...

API maker Bright Green plans $3.5B US facilities; EU launches biotech hub; Q4 earnings from Thermo Fisher, Sartorius, Danaher; Piramal reports growth; Upperton completes UK site ...

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with ...

Often people create flows to call Microsoft Graph end points or Approval from within Power Apps rather than "Power Automate ...

NICE, in collaboration with other international health technology assessment agencies, has published a new report which ...

Attackers from the Lazarus group used social engineering tactics to impersonate recruiters and gain access to systems in a ...

The layoffs will allow Ironwood to dedicate more resources to pushing its lead molecule apraglutide through a Phase III trial ...

Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and ...

There are no validated definitions of remission or of significant improvement for these indices. The use of clinically important end points would strengthen the validity of study outcomes. Our aims ...

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...